Search
forLearn
5 / 801 resultslearn PTT-6®
learn pyrrolidone carboxylic acid
learn APISCALP™
learn PTD-DBM
Research
5 / 35 results
research 1369 Terminalia chebula fruit extract from PSR™ technology demonstrates strong anti-aging and antioxidant properties
Terminalia chebula fruit extract has strong anti-aging and antioxidant effects.
research Cold Plasma An emerging technology for clinical use in wound healing
Cold Plasma shows promise for healing wounds by killing bacteria and helping tissue grow.
research 1371 Impact of temperature on sprouted seeds in botanical extracts obtained with different extraction processes
Cold temperatures reduce sprouted seed extract yield, but PSR™ technology produces extracts with more beneficial compounds than conventional methods.
research Production and Characterization of Wool and Hair Fibers in Highlands of Baluchistan, an Economic and Sustainable Approach for Pakistan
Improving skills and technology in Baluchistan's wool industry could boost quality, jobs, and Pakistan's economy.
research Laser Resurfacing
Newer skin resurfacing lasers reduce damage and scarring, with some approved for safe use and minimal side effects.
Community Join
5 / 1000+ results
community The story of RU58841/ PSK3841
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Hy-tissue PRP 50 Experience ??
PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.